Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Xolair Average Cost Is $10,000 A Year; Mid-July Launch Planned

Executive Summary

Genentech/Novartis' allergic asthma treatment Xolair will cost about $10,000 a year for the average patient at mid-July launch
Advertisement

Related Content

Phase IV Commitments For Registries Likely To Increase, Genentech Says
Phase IV Commitments For Registries Likely To Increase, Genentech Says
Genentech Xolair Covered Under Patent License, PDL Says; Seeks Royalties
Genentech Xolair Covered Under Patent License, PDL Says; Seeks Royalties
Genentech Avastin Supply Will Come From Two Sites; BLA Coming Soon
Genentech Avastin Supply Will Come From Two Sites; BLA Coming Soon
Xolair Population Is 500,000, Genentech Says; Prior Authorization Expected
Xolair Allergic Asthma Population Should Not Be Restricted Except By Age
Xolair Allergic Asthma Population Should Not Be Restricted Except By Age
Advertisement
UsernamePublicRestriction

Register

PS042006

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel